Compare DAKT & ORIC Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | DAKT | ORIC |
|---|---|---|
| Founded | 1968 | 2014 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Office Equipment/Supplies/Services | Biotechnology: Pharmaceutical Preparations |
| Sector | Industrials | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 944.7M | 861.3M |
| IPO Year | 1996 | 2020 |
| Metric | DAKT | ORIC |
|---|---|---|
| Price | $19.12 | $7.28 |
| Analyst Decision | | Strong Buy |
| Analyst Count | 0 | 13 |
| Target Price | N/A | ★ $19.73 |
| AVG Volume (30 Days) | 238.2K | ★ 1.5M |
| Earning Date | 03-04-2026 | 05-05-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | ★ 19.67 |
| EPS | ★ 0.75 | N/A |
| Revenue | ★ $608,932,000.00 | N/A |
| Revenue This Year | $12.06 | N/A |
| Revenue Next Year | $9.16 | N/A |
| P/E Ratio | $25.97 | ★ N/A |
| Revenue Growth | ★ 6.89 | N/A |
| 52 Week Low | $13.30 | $7.23 |
| 52 Week High | $28.27 | $14.93 |
| Indicator | DAKT | ORIC |
|---|---|---|
| Relative Strength Index (RSI) | 40.01 | 37.14 |
| Support Level | $18.96 | N/A |
| Resistance Level | $19.38 | $13.89 |
| Average True Range (ATR) | 0.54 | 0.51 |
| MACD | -0.09 | 0.00 |
| Stochastic Oscillator | 10.28 | 18.46 |
Daktronics Inc designs and manufactures electronic scoreboards, programmable display systems, and large-screen video displays for sporting, commercial, and transportation applications. It is engaged in a full range of activities: marketing and sales, engineering and product design and development, manufacturing, technical contracting, professional services, and customer service and support. The company offers a complete line of products, from small scoreboards and electronic displays to large multimillion-dollar video display systems as well as related control, timing, and sound systems. The company has five reportable segments: Commercial, Live Events, High School Park and Recreation, Transportation, and International. The company makes the majority of its revenue from Live events.
ORIC Pharmaceuticals Inc is a clinical-stage biopharmaceutical company. It has a pipeline of therapies designed to counter resistance mechanisms in cancer by leveraging its expertise within three specific areas: hormone-dependent cancers, precision oncology, and key tumor dependencies. The company has product candidates namely ORIC-944, ORIC-114, and ORIC-533. The Company has as one operating segment, focused on the discovery and development of therapies designed to counter the resistance mechanisms in cancer.